Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MGAT2 | Q10469 | 3/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311233 | 0.91 | HTT (0.35) | SGK1PTGS2 | |
| SCHEMBL3310669 | 0.81 | KDM4E (0.37) | SGK1PDE2APDE10A | |
| SCHEMBL3966184 | 0.80 | RAPGEF4 (0.38) | PTGS2CYP11B1CYP11B2MAPK14 | |
| SCHEMBL3311229 | 0.76 | RAPGEF4 (0.35) | PTGS2CYP11B1CYP11B2 | |
| SCHEMBL3311725 | 0.74 | KDM4E (0.37) | SGK1PDE2APDE10A | |
| SCHEMBL2040694 | 0.74 | PDE10A (0.41) | PDE10A | |
| SCHEMBL1873945 | 0.73 | KMT2A (0.34) | — | |
| SCHEMBL2355414 | 0.72 | MEN1 (0.47) | — | |
| SCHEMBL3311645 | 0.70 | ERBB2 (0.37) | CYP11B1CYP11B2MGAT2 | |
| SCHEMBL2355084 | 0.69 | CASP1 (0.39) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2121629-A1 | NOVEL PYRIDAZINE DERIVATIVES | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008049584-A1 | NOVEL PYRIDAZINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113457-A1 | NOVEL PYRIDAZINE DERIVATIVES | C3AR1, C5, C1S | SGK1 4090/4885PTGS2 1613/4885CYP11B1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.